Nevro Stock Performance Shares of NVRO stock opened at $5.85 on Monday. Nevro Corp. has a 12 month low of $3.17 and a 12 month high of $11.65. The company has a debt-to-equity ratio of 0.67, a ...

On December 1, 2024, Nevro Corp. became aware of a security incident on its network. Upon detection, Nevro launched an investigation with the assistance of third-party cyber security experts to ...

O'Boyle is an Independent Director at Outset Medical, Inc., an Advisor at HighCape Capital Acquisition Corp. II and an Advisor at HighCape Partners Management LLC. He is on the Board of Directors at ...

Discover key Q1 2025 insights from Globus Medical, including revenue trends, the Nevro acquisition, free cash flow growth, and future strategies.

Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to ...

Despite revenue challenges, Globus Medical Inc (GMED) reports significant free cash flow growth and strategic acquisitions to ...

His previous board service includes Nevro Corp., which was acquired by Globus Medical, Inc. in April 2025, and GenMark Diagnostics, which was taken over by Roche in May 2021. O’Boyle also has ...

What are some key companies Kevin O’Boyle has worked with? Kevin O’Boyle has worked with Nevro Corp., GenMark Diagnostics, and NuVasive, among others in the medical device sector. Dale E.

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) ("Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and ...